Unicycive Therapeutics, Inc (UNCY): Bathi resik saben saham (EPS TTM)

The absence of commercial sales due to the R&D stage eliminates current profits for Unicycive Therapeutics (UNCY). This 12-month EPS chart on GURU.Markets contains data where this metric equals -1.51. Effective budget management supports the development of kidney therapy, while the patent purity of the innovative oral drug creates potential for expansion into a high-margin market.
Rincian analitis lan laporan data perusahaan Unicycive Therapeutics (UNCY)

This metric aggregates net income over a rolling year, excluding quarterly anomalies and accounting distortions. It measures the actual efficiency of profit generation per ordinary share. For Unicycive Therapeutics (UNCY), this indicator reflects the monetization of patents for innovative drugs treating hyperphosphatemia. The capitalization of its technological advantage over conventional medications directly impacts the financial result. The trend of current earnings per share over the last 12 months confirms the transparency of the business model.